To evaluate whether daily oral micronized progesterone is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.
To evaluate whether 400 mg daily oral micronized progesterone from 16 to 34 weeks' is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
36
oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
Miami Valley HospitaL
Dayton, Ohio, United States
Rate of Recurrent Preterm Birth
Spontaneous preterm birth prior to 37 weeks' gestation. Indicated preterm deliveries (for maternal or fetal reasons) were excluded.
Time frame: Prior to 37 weeks' gestation
Secondary Outcomes
Serum progesterone levels
Time frame: Mean +/- Std Dev gestational age of 25.9/-2.4 weeks in Progesterone group, and 28.4 +/-4.7 weeks in placebo group
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.